miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense
Radiotherapy is essential to the treatment of most solid tumors and acquired or innate resistance to this therapeutic modality is a major clinical problem. Here we show that miR-139-5p is a potent modulator of radiotherapy response in breast cancer via its regulation of genes involved in multiple DNA repair and reactive oxygen species defense pathways. Treatment of breast cancer cells with a miR-139-5p mimic strongly synergized with radiation both in vitro and in vivo, resulting in significantly increased oxidative stress, accumulation of unrepaired DNA damage, and induction of apoptosis. Several miR-139-5p target genes were also strongly predictive of outcome in radiotherapy-treated patients across multiple independent breast cancer cohorts. These prognostically relevant miR-139-5p target genes were used as companion biomarkers to identify radioresistant breast cancer xenografts highly amenable to sensitization by cotreatment with a miR-139-5p mimetic.Significance: The microRNA described in this study offers a potentially useful predictive biomarker of radiosensitivity in solid tumors and a generally applicable druggable target for tumor radiosensitization. Cancer Res; 78(2); 501-15. (c)2017 AACR.
|ISBN||1538-7445 (Electronic) 0008-5472 (Linking)|
|Authors||Pajic, M.; Froio, D.; Daly, S.; Doculara, L.; Millar, E.; Graham, P. H.; Drury, A.; Steinmann, A.; de Bock, C. E.; Boulghourjian, A.; Zaratzian, A.; Carroll, S.; Toohey, J.; O'Toole, S. A.; Harris, A. L.; Buffa, F. M.; Gee, H. E.; Hollway, G. E.; Molloy, T. J.|
|Responsible Garvan Author|
|Publisher Name||CANCER RESEARCH|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/29180477|